The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma

European Journal of Haematology

Volumn 61, Issue 5, 1998, Pages 306-310

  Schey, S A ^a   Kazmi, M ^a   Ireland, R ^a   Lakhani, A ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Dexamethasone; Intermediate dose melphalan; Multiple myeloma

Indexed keywords

DEXAMETHASONE; INTERFERON; MELPHALAN; PARAPROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 0031797956     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01093.x     Document Type: Article

References (21)

1. ALEXANIAN R, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680.
2. SPORN JR, MCINTYRE OR. Chemotherapy of previously untreated myeloma patients: an analysis of recent treatment results. Semin Oncol 1980;13:318-325.
3. OKEN MM, HARRINGTON DP, ABRAMSON N, et al. Comparison of MP with VBMCP for the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79:1561-1567.
4. MACLENNAN IC, KELLY K, CROCKSON RA, et al. Results of the MRC myelomatosis trials for patients entered since 1980. Haematol Oncol 1988;6:145-158.
5. MACLENNAN IC, CHAPMAN C, DUNN J, et al. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992;339:200-205.
6. GREGORY WM, RICHARDS MA, MALPAS JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
7. MCELWAIN T, POWLES RL. High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983;ii:822-824.
8. SELBY PJ, MCELWAIN TJ, NANADI AC, et al. Multiple myeloma treated with high dose melphalan. Br J Haematol 1987;66:55-62.
9. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-854.
10. SALMON SE. Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 1975;45:119-128.
11. BELL JBG, MILLAR JA, MAITLAND JA, et al. Increased clonogenic tumour cells in bone marrow after VAMP therapy. Lancet 1988;ii:931-933.
12. BERGSAGEL DE. Melphalan/prednisolone versus drug combinations for plasma cell myeloma. Eur J Haematol 1989;(Suppl) 51:117-123.
13. BOCCADORO M, PALUMBO A, ARGENTINO C, et al. Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 1997;96:333-337.
14. LOKHORST HM, SONNEVLD P, WIJERMANS PW, et al. Intermediate dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol 1996;92: 1:44-48.
15. SAMSON D, NEWLANDS A, KEARNEY J, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as firstline therapy for multiple myeloma. Lancet 1989:882-885.
16. CUNNINGHAM D, PAZ-ARES L, GORE ME, et al. High dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994;12:764-768.
17. 2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. Eur J Haematol 1989;42:233-237.
18. TSAKANIKAS S, PAPANASTASIOU K, STAMATELOU M, MANIATIS A. Intermediate dose of intravenous melphalan in advanced multiple myeloma. Oncology 1991;48:369-371.
19. BACK H, LINDBLAD R, RODJER S, WESTIN J. Single dose intravenous melphalan in advanced multiple myeloma. Acta Haematol 1990;83:183-186.
20. ALEXANIAN R, BARLOGIE B, DIXON D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
21. ALEXANIAN R, DIMOPOUPOS MA, DELA SALLE K, BARLOGIE B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-890.